INFORMATION BY CANCER TYPE
Sumanta Kumar Pal, M.D., associate professor, Department of Medical Oncology, City of Hope, covered the scope of exciting genitourinary cancer data presented at the 2017 ESMO Congress, with a sharp focus on the CABOSUN and CheckMate-214 trials.
The latest drugs for advanced kidney cancer are stirring optimism.
The Food and Drug Administration approved the first ever biosimilar to treat a variety of cancers.
In an interview with CURE, Badani, a professor of Urology at Mount Sinai Hospital, discusses the benefits of robotic surgery in RCC.
Cabometyx had better progression-free survival rates than Sutent (sunitinib) for certain patients with renal cell carcinoma.
Progression-free survival (PFS) was not significantly improved with the combination of dalantercept plus Inlyta (axitinib) in patients with advanced renal cell carcinoma (RCC) compared with placebo, according to the results from the phase 2 DART trial.
Bavencio and Inlyta together produced a promising response for some patients with renal cell carcinoma.
There are 16 known genes that cause kidney cancer and at least 13 different types of inherited kidney cancer, emphasizing the need to understand genetic differences between these disease.
Metastatic Kidney Cancer or a Separate Lung Cancer? Expert Urges Patients, Doctors to Learn the Difference
James Brugarolas, M.D., Ph.D., discusses the importance of spotting the difference between a metastatic kidney cancer lesion and a separate lung cancer. The difference can save patients' lives.
David McDermott, M.D. discusses new advances made to treat kidney cancer.